Despite having a substantial $401 million in funding, ElevateBio is streamlining its operations, resulting in job cuts that will impact 13% of its workforce.
A spokesperson from ElevateBio emphasized the company’s strong financial position, stating that they have the resources needed for future growth and sustainability. However, to better focus on their areas of strength and growth, ElevateBio has made the decision to prioritize its BaseCamp genomic medicine process development and manufacturing work, along with the Life Edit gene editing platform. This strategic shift involves reducing pre-clinical work in certain therapeutic programs that are still several years away from clinical trials, resulting in a 13% reduction in the workforce.
The exact number of employees affected by these layoffs has not been specified, but the company is currently listed as having around 500 employees on LinkedIn.
Also Read: September Layoffs: A Recap Of Recent Workforce Reductions In Biotech And Pharma
ElevateBio made headlines earlier this year with a significant $401 million series D fundraising round, which is among the largest in the biotech industry in 2023, a year marked by funding challenges for many companies. The company has experienced a transformative year, with 20 industry partners collaborating on gene editing, cGMP manufacturing, and RNA engineering. Notable partners include Moderna and Novo Nordisk, who joined ElevateBio in February and May, respectively.
The spokesperson emphasized ElevateBio’s strong financial position and robust customer and revenue growth, underlining their commitment to allocating substantial resources to meet the increasing industry demand for ElevateBio’s BaseCamp and Life Edit technologies and capabilities.
ElevateBio’s strategic realignment and continued growth trajectory demonstrate its adaptability and commitment to meeting the evolving demands of the biotech sector.
